July 2015, Volume 1, Issue 7

July 2015

Volume 1, Issue 7

This month, we uncover the potential pitfalls of precision medicine, report on the latest hematologic research from the American Society of Clinical Oncology annual meeting and European Hematology Association Congress, and more.

Table of Contents

July 2015

Crossing the Generational Divide

Wednesday, July 1st, 2015
“Millennials” or “Generation Y,” those of us born in the early 1980s who came of age around the turn of the century, don’t have...

Benign Hematology Isn’t So Benign

Wednesday, July 1st, 2015
As a benign hematologist, I get a lot of questions about what I do and the kind of medicine I practice. When my parents want...

Help Us Help You: Enhancing APP Productivity

Wednesday, July 1st, 2015
More than ever, hematology and oncology practices are relying on advanced practice providers (APPs; nurse practitioners and physician assistants ) to fill the...

July 2015

Blood Journal’s Impact Factor, ASH Annual Meeting Abstract Submission Open, and more

Wednesday, July 1st, 2015
Blood Journal’s Impact Factor the Highest Since 2010; First in Field of Hematology The Thomson Reuters’ Journal Citation Report®, released in June, revealed Blood’s impact...

Remembering Robert Arceci and Gerald Logue, Pew-Stewart Scholars Announced, and more

Wednesday, July 1st, 2015
Robert J. Arceci, MD, PhD (1950-2015) Robert J. Arceci, MD, PhD, a pediatric oncologist from Phoenix Children’s Hospital in Arizona, was killed June 8 in...

July 2015

Pulling Back the Curtain: Wendy Stock, MD

Wednesday, July 1st, 2015
What was your first job? My first job was working at a Dairy Queen. I worked there the summer before I turned 16 and, actually,...

Decoding Genomic Profiling: The Hype and the Hope of Precision Medicine

Wednesday, July 1st, 2015
Genetic assays, new sequencing platforms, and growing evidence about the role mutations play in malignancies and cancer risk have given hematologists and oncologists more...

July 2015

Anticoagulation recommendations for a young patient who developed DVT after knee surgery, and then...

Wednesday, July 1st, 2015
This month, Alice J. Cohen, MD, advises on the choice of anticoagulation in a patient who developed pulmonary embolism after knee surgery.A 28-year-old male...

Teaching Physicians Communications Skills

Wednesday, July 1st, 2015
Here’s a patient scenario you might have encountered: One day, a patient with a highly curable cancer is admitted to our hospital, but he...

July 2015

WIB_icon

Nilotinib Plus Chemotherapy Yields Encouraging Results for Patients with Ph-Positive ALL

Wednesday, July 1st, 2015
Nilotinib, when used in combination with multi-agent chemotherapy, achieved “deep” molecular responses similar or better than those achieved with imatinib in patients with Philadelphia-positive...

New Therapeutic Targets for Patients with Leukemia

Wednesday, July 1st, 2015
In a recent study published in Cancer Research, investigators were able to identify mutations in the anaplastic lymphoma kinase (ALK) genes in a small...
WIB_icon

Can Splanchnic Venous Thrombosis Predict Subsequent Cancer Diagnosis?

Wednesday, July 1st, 2015
Research has shown that embolic events put patients at an increased risk for developing cancer: Venous thromboembolism (VTE) may represent a marker for occult...

Viral History from a Single Drop of Blood, NCI Launches Gene Therapy Trial, FDA...

Wednesday, July 1st, 2015
Going Viral: A New Test Detects Lifetime Virus Exposure with a Single Drop of Blood VirScan, a recently developed, high-throughput blood test, can detect nearly...

Dormant Leukemia Cells May “Reawaken” During Late Relapse

Wednesday, July 1st, 2015
Some patients deemed “cancer-free” can experience disease recurrence or relapse years after diagnosis and treatment, without any apparent cause. According to a paper published...

High Immunoglobulin E Levels: A Cause for Concern in Cancer Risk?

Wednesday, July 1st, 2015
While it is common knowledge that immunoglobulin E (IgE) is produced by plasma cells as part of an allergic immune response, are plasma IgE...

For Perioperative Anticoagulation in Atrial Fibrillation: Burn Those Bridges

Wednesday, July 1st, 2015
When patients with atrial fibrillation (AF) being treated with warfarin need to interrupt anticoagulation to undergo an elective operation or invasive procedure, the common...
WIB_icon

New Insights into Transformed Follicular Lymphoma from the National LymphoCare Study

Wednesday, July 1st, 2015
Patients with follicular lymphoma (FL) whose cancer has transformed into diffuse large B-cell lymphoma (DLBCL) often have a poor prognosis, with overall survival of...

Vena Cava Filters Not Worth the Risk in Patients with Acute Pulmonary Embolism Receiving...

Wednesday, July 1st, 2015
Over the past three decades, inferior vena cava (IVC) filters have been used much more frequently as an add-on to anticoagulation therapy in patients...
WIB_icon

Long-Term Study Finds Cladribine Safe, Effective Across All Subtypes of Mastocytosis

Wednesday, July 1st, 2015
Ten-year follow-up data from a recent retrospective study published in Blood suggest that cladribine (2-CdA) is an effective and safe treatment option for patients...

July 2015

Study Finds Clinical Benefit for ERY001 in ALL

Wednesday, July 1st, 2015
Asparaginase is a commonly prescribed treatment option for acute lymphocytic leukemia (ALL), but its use can be limited by its toxicities, including drug hypersensitivity....

The DNMT3A R882 Mutation’s Impaired DNA-Damage Sensing: A Key to Overcoming Chemoresistance in AML

Wednesday, July 1st, 2015
A study presented at the 2015 European Hematology Association Congress suggests an important role for DNMT3A R882 mutations in chemoresistance in acute myeloid leukemia...

Early Trials in AML and CMML Offer Promising Results

Wednesday, July 1st, 2015
In early-phase trials conducted in patients with acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), two investigational agents (ASP2215 and CPI-613) and one...

ELOQUENT-2: Adding Elotuzumab to Standard Therapy Reduces Progression Risk for Multiple Myeloma Patients

Wednesday, July 1st, 2015
According to interim results of the phase III, randomized, open-label ELOQUENT-2 study, elotuzumab may offer a new treatment option for patients with relapsed multiple...

Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory CLL

Wednesday, July 1st, 2015
An early-phase study of the combination of venetoclax, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, with rituximab showed response rates of 80 percent...

Inotuzumab Ozogamicin Improves Complete Remission in Poor-Prognosis ALL

Wednesday, July 1st, 2015
Inotuzumab ozogamicin (InO), an investigational anti-CD22 antibody drug conjugate, demonstrated a higher complete hematologic remission rate in adult patients with relapsed or refractory CD22-positive...

High Response Rates for Brentuximab Vedotin Combinations in HL and DLBLC

Wednesday, July 1st, 2015
High response rates were the hallmark of two clinical trials of brentuximab vedotin (BV) in combination with chemotherapy presented at the 2015 American Society...

Treating the High-Risk APL Patient: ATRA + ATO + GO Might Be the Key

Wednesday, July 1st, 2015
While the combinations of all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO; ATRA+ATO) and of ATRA+ATO plus gemtuzumab ozogamicin (GO; ATRA+ATO+GO) have yielded good clinical...

In Multiple Myeloma, Carfilzomib Bests Bortezomib, But Bortezomib Bests Observation

Wednesday, July 1st, 2015
Two multiple myeloma (MM) studies – one in relapsed disease and the other in newly diagnosed disease after autologous stem cell transplantation (ASCT) –...

PI3K Inhibitors Safe and Effective in CLL Patients

Wednesday, July 1st, 2015
Updated data on the safety and effectiveness of three different phosphoinositide 3-kinase inhibitors (PI3K inhibitors) presented at the European Hematology Association (EHA) Congress show...

SHARE